[Neuromuscular blockade using vecuronium in dermatomyositis].
The significant features of neuromuscular blockade with vecuronium in a patient with dermatomyositis are described: vecuronium 0.08 mg/kg resulted in 90%, 0.12 mg/kg in 100% neuromuscular blockade. In contrast to claims made in some previous publications, dermatomyositis did not produce increased sensitivity to vecuronium. Onset time and duration of action were also within normal limits in our patient. Time of spontaneous recovery until antagonism with neostigmine was markedly prolonged, but the dermatomyositis was only one of various possible explanations. Although there are potential hazards in the use of neostigmine in patients with dermatomyositis, antagonism of the neuromuscular block with 2 mg neostigmine was without problems in our patient. Our data support recent suggestions to reconsider the implications of dermatomyositis for anesthesia.
Mair
P
P
Klinik für Anaesthesie und Allgemeine Intensivmedizin, Universität Innsbruck.
Mitterschiffthaler
G
G
Hohlböck
E
E
D000368:Aged; D003882:Dermatomyositis / Q000503:physiopathology*; D005260:Female; D006801:Humans; D009469:Neuromuscular Junction / Q000187:drug effects* / Q000503:physiopathology; D014673:Vecuronium Bromide / Q000494:pharmacology*
D014673:Vecuronium Bromide
Neuromuskuläre Blockade mit Vecuronium bei Dermatomyositis.